Glycosa
  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations
  • More
    • Home
    • Introduction
    • Status of the MVP
    • Strategic Partnerships
    • Current Stages
    • Human Trials and Promise
    • Team
    • Investor Relations
Glycosa
  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations
data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=
A Pioneering Non-Invasive Blood Glucose Monitoring:

A Dream come true ...

First time in the world, backed by human clinical trials, the GLYCOSA device combines multilayered AI and innovative sensors to monitor blood glucose without the blood sample/needle prick, and with high accuracy in humans.

Find out more

Real-Time Blood Glucose Monitoring

  • Completely non-invasive
  • Utilizes powerful Artificial Intelligence
  • Up-to-date technology
  • Personalization feature
  • Use of multiple sensors
  • Ease of use for everyone
  • No consumable parts (environmentally friendly)
  • Reasonably and competitively priced
  • Mobile connection and disease management


STATUS OF THE MVP
Resolved Painpoints

Differentiated Value

Our technology provides differentiated value by measuring the glucose directly from the blood in veins and capillaries.


Resolved Painpoints:


A. No painful needle pricks

B. Eliminate higher costs of replenishing supplies such as test-strips and CGM sensors

C. Eliminate the LAG time in Blood Glucose measurements with CGM’s

The best app for diabetes control

Say Goodbye to Diabetes

  • Everything a diabetic needs
  • Use powerful artificial intelligence
  • Draw graphs of blood glucose changes during the day, month, year
  • Calculate HbA1C
  • Calculating the effects of meals, drugs, and daily activities on blood glucose
  • Share the results real-time with the doctor
  • Help  to control and cure the disease

Reliable Accuracy

We tested our device on human subjects by partnering with laboratories for two years. During this time we have performed more than 7000 clinical tests on human patients. The average accuracy of the lastest version of our device is  ~ 88.5% (or  ~ 11.5% - Mean Absolute Percentage Error (MAPE)).

Human Trials

Non-Invasive Blood Glucose For a Healthier Life - TARGET MARKET SEGMENTS

#

DIABETES-Blood Glucose

#

Body Weight-Blood Glucose

#

Effect of meals-Blood Glucose

Glycosa® aims to disrupt the global market for blood glucose monitoring devices by eliminating the existing consumer pain points (needle pricks, expensive, infection etc.) and provide a differentiated value to consumers by enabling a blood glucose measurement by simple touch interface.


Pradeep Karla, Ph.D., Stanford LEAD (CEO)

ABOUT US

Our team was founded by a group of creative and entrepreneurial people to improve quality of life and patient care through continuous non-invasive monitoring of blood glucose.

For this reason, this group has conducted extensive tests and studies in the field since 2019 and has succeeded in designing accurate blood glucose measuring devices with affordable prices and unique features. The clinical trial of our device has now been completed, and we are prepared to launch our brand in the global market as a brand with distinctive technology and high accuracy for the first time in the world.




our team

Contact Us

We will be in touch!

Attach Files
Attachments (0)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations

Copyright © 2024 GLYCOSA - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept